Back to Search Start Over

Satraplatin Demonstrates High Cytotoxic Activity Against Genetically Defined Lymphoid Malignancies

Authors :
THILO ZANDER
JIA XUE
GABRIEL MARKSON
FELIX DAHM
CHRISTOPH RENNER
Source :
Anticancer Research. 42:1821-1832
Publication Year :
2022
Publisher :
Anticancer Research USA Inc., 2022.

Abstract

Satraplatin is an oral platinum analog with proven clinical efficacy and a more favorable toxicity profile, although with increased hematotoxicity, when compared to cisplatin. Hence, we carried out a systematic biomarker analysis to identify hematological malignancies with high susceptibility to satraplatin.Half-maximal inhibitory concentrations (ICSatraplatin was significantly more active against hematological malignancies compared to solid organ cancer. In addition, satraplatin showed a significantly more potent antiproliferative activity compared to cisplatin in most lymphoma cell lines achieving sub micromolar ICSatraplatin demonstrated a high cytotoxic activity in genetically well-defined hematological malignancies which is distinct from that of cisplatin. MTAP deficiency was identified as biomarker of enhanced satraplatin efficacy in hematological cancer-derived cell lines. These data in combination with the lipophilicity of satraplatin provide the rationale for targeting specific lymphatic entities such as primary central nervous system lymphoma and cutaneous T-cell lymphoma to improve clinical outcome.

Details

ISSN :
17917530 and 02507005
Volume :
42
Database :
OpenAIRE
Journal :
Anticancer Research
Accession number :
edsair.doi.dedup.....88c4b38ed4c96861f90fd2d18e1697f3
Full Text :
https://doi.org/10.21873/anticanres.15658